Subtype
Intracranial Neoplasm
CI-CAN-00001030Explore in graph →
Non-malignant521 active trials34 evidence items
- NCIt
- C4953
Loading cancer entity…
Subtype
CI-CAN-00001030Explore in graph →
Clinical trials
2,177 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | active not recruiting | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02792582 | A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection | active not recruiting | Phase 2 | 160 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03197506 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | active not recruiting | Phase 2 | 52 | Mayo ClinicOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT01089101 | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | active not recruiting | Phase 1 / Phase 2 | 217 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT05050929 | RAPid SimPLE Targeted Radiation Treatment for Brain Metastases(RAPPLE) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03158064 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03508752 | Neurocognitive Decline in Patients With Brain Metastases | active not recruiting | Phase 1 / Phase 2 | 80 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01419067 | A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection | active not recruiting | Phase 2 | 112 | St. Jude Children's Research HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06777433 | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases(RAD101) | active not recruiting | Phase 2 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT02691923 | Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker | active not recruiting | Phase 2 | 30 | David W. RobertsOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04743661 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | active not recruiting | Phase 2 | 62 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT02886585 | Pembrolizumab In Central Nervous System Metastases | active not recruiting | Phase 2 | 101 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02724579 | Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma | active not recruiting | Phase 2 | 45 | Children's Oncology GroupNETWORK | 5 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03220646 | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | active not recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03224767 | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | active not recruiting | Phase 2 | 24 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04074096 | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis(BEPCOME-MB) | active not recruiting | Phase 2 | 10 | UNICANCEROTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04690348 | Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study | active not recruiting | Phase 2 | 103 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05128903 | Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study | active not recruiting | Phase 2 | 22 | St. Jude Children's Research HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05615623 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | active not recruiting | Phase 1 / Phase 2 | 10 | InSightecINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05630209 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | active not recruiting | Phase 1 / Phase 2 | 10 | InSightecINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05267587 | Preop fSRS for Resectable Brain Metastases | active not recruiting | Phase 2 | 49 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05733572 | Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)(NGF-OPG) | active not recruiting | Phase 2 | 36 | Benedetto FalsiniOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05503251 | Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases | active not recruiting | Phase 2 | 110 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT02374242 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases(ABC) | active not recruiting | Phase 2 | 76 | Melanoma Institute AustraliaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02066220 | International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | active not recruiting | Phase 2 / Phase 3 | 360 | Universitätsklinikum Hamburg-EppendorfOTHER | 16 | Dec 4, 2025 | clinicaltrials |
| NCT01878617 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | active not recruiting | Phase 2 | 660 | St. Jude Children's Research HospitalOTHER | 4 | Nov 13, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT06020066 | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI | active not recruiting | Phase 2 | 202 | Fudan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05139043 | Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors | active not recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials